<div id=toc></div>

# Table of Contents

- [q-bio.QM](#q-bio.QM) [Total: 1]


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [1] [Mechanistic Learning for Survival Prediction in NSCLC Using Routine Blood Biomarkers and Tumor Kinetics](https://arxiv.org/abs/2601.11148)
*Ruben Taieb,René Bruno,Pascal Chanu,Jin Yan Jin,Sébastien Benzekry*

Main category: q-bio.QM

TL;DR: 该研究开发了TALN-k机制模型，结合肿瘤负荷与三种血液标志物动力学，并通过机器学习框架TALN-kML预测非小细胞肺癌患者总生存期，在临床试验数据上验证了其优越性能。


<details>
  <summary>Details</summary>
Motivation: 预测非小细胞肺癌患者总生存期对临床决策和药物开发至关重要。肿瘤标志物和血液标志物动力学之间存在内在联系，但它们的联合动态及其与总生存期的关系尚不清楚。

Method: 开发了TALN-k机制模型，通过耦合微分方程捕捉肿瘤负荷与三种关键血液标志物（白蛋白、乳酸脱氢酶、中性粒细胞）动力学的相互作用。进一步结合机器学习框架TALN-kML进行总生存期预测。使用非线性混合效应模型估计参数，在atezolizumab单药治疗（862例）和联合治疗（1115例）的NSCLC患者临床试验数据上进行训练和验证。

Result: TALN-k模型成功描述了标志物动力学，显著改善了校正BIC和对数似然指标。特征选择方法识别出有价值的预测参数。TALN-kML模型在总生存期预测方面优于经验模型，C指数（0.74±0.02 vs 0.72±0.03）、12个月AUC（0.83±0.004 vs 0.79±0.05）和准确率（0.77±0.03 vs 0.76±0.05）均有提升。

Conclusion: 该机制学习方法提供了可解释的模型，通过联合整合肿瘤和血液标志物动力学，改善了NSCLC纵向数据描述和生存预测。该方法为个性化治疗策略和药物开发优化提供了有前景的途径。

Abstract: Background Predicting overall survival (OS) in non-small cell lung cancer (NSCLC) is essential for clinical decision-making and drug development. While tumor and blood test markers kinetics are intrinsically linked, their joint dynamics and relationship to OS remain unknown. Methods We developed a mechanistic model capturing the interplay between tumor (T) burden and three key blood markers kinetics: albumin (A), lactate dehydrogenase (L), and neutrophils (N), through coupled differential equations (termed TALN-k). This model was enhanced with a machine learning framework (TALN-kML) for OS prediction. The model was trained and validated on clinical trial data from NSCLC patients treated with atezolizumab in monotherapy (N = 862 patients) or combination therapy (N = 1,115). Model parameters were estimated using nonlinear mixed-effects modelling, and survival predictions were assessed using individual and trial level metrics. Results TALN-k successfully described individual and population-level marker kinetics, revealing complex interactions between tumor and blood markers, and improving corrected BIC and log-likelihood metrics by a significant margin of previous empirical state-of-the-art models. Feature selection methods also highlighted valuable predictive parameters, indicatives of good or poor prognosis. The TALN-kML model outperformed empirical, uncoupled models, achieving improved C-index (0.74 $\pm$ 0.02 vs 0.72 $\pm$ 0.03), 12-months AUC (0.83 $\pm$ 0.004 vs 0.79 $\pm$ 0.05), and accuracy (0.77 $\pm$ 0.03 vs 0.76 $\pm$ 0.05) in OS prediction. Conclusion Our mechanistic learning approach allows for an interpretable model, which improves on longitudinal data description and on survival prediction in NSCLC by jointly integrating tumor and blood markers kinetics. This methodology offers a promising avenue for both personalized treatment strategies and drug development optimization.

</details>
